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Abstract 
Background- Protease nexin-1 (PN-1) is a serpin that inhibits plasminogen activators, 
plasmin and thrombin. PN-1 is barely detectable in plasma, but we have recently shown that 
PN-1 is present within the alpha-granules of platelets. 
Methods and Results- In this study, the role of platelet PN-1 in fibrinolysis was investigated 
using human platelets incubated with a blocking antibody and platelets from PN-1-deficient 
mice. We showed by using fibrin-agar zymography and fibrin matrix that platelet PN-1 
inhibited both the generation of plasmin by fibrin-bound tPA, and the activity of fibrin-bound 
plasmin itself. Rotational thromboelastometry (ROTEM®
Conclusion- Our results reveal that platelet PN-1 can be considered as a new important  
) and laser scanning confocal 
microscopy were used to demonstrate that PN-1 blockade or deficiency resulted in increased 
clot lysis and in an acceleration of the lysis front. PN-1 is thus a major determinant of the 
lysis-resistance of platelet-rich clots (PRCs). Moreover, in an original murine model in which 
thrombolysis induced by tPA can be measured directly in situ, we observed that vascular 
recanalization was significantly increased in PN-1-deficient mice. Surprisingly, general 
physical health, after tPA-induced thrombolysis, was much better in PN-1-deficient than in 
wild-type mice. 
regulator of thrombolysis in vivo. Inhibition of PN-1 is thus predicted to promote endogenous 
and exogenous t-PA-mediated fibrinolysis, and may enhance the therapeutic efficacy of 
thrombolytic agents. 
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Introduction 
 Vascular injury and subsequent thrombus formation are key events in the pathogenesis 
of atherothrombosis and venous thromboembolism. The serine proteases, urokinase- and 
tissue-type plasminogen activators (uPA and tPA respectively), generate plasmin which 
drives fibrinolysis. The thrombolytic actions of these proteases are critical for clot dissolution. 
Their properties have numerous therapeutic applications, including fibrinolysis for ST 
elevation myocardial infarction (STEMI). Direct recanalization of an occluded vessel by 
primary angioplasty became the preferred reperfusion strategy in STEMI patients. 
Thrombolysis remains however, an option of reperfusion therapy in early STEMI presenters. 
Despite early administration of recombinant tPA in STEMI presenters, fibrinolysis fails to 
achieve myocardial reperfusion in one out of two patients and is associated with poor clinical 
outcome1. This phenomenon is of considerable clinical importance in the setting of acute 
myocardial infarction, because early restoration of normal blood flow is strongly associated 
with improved survival. A few factors have been identified to be involved in this inter-
individual heterogeneity, such as age, delay between symptom onset and fibrinolytic therapy, 
smoking habit, infarct size and site2
 Plasminogen activator inhibitor type-1 (PAI-1) is a serine protease inhibitor which is 
present in plasma and in platelet α-granules. An increased plasma concentration of PAI-1 has 
been associated with recurrent myocardial infarction
. 
3, 4. In humans, platelet PAI-1 is assumed 
to be a major contributor to the stabilization of the thrombus, by inhibiting endogenous 
fibrinolysis5, 6. However, platelets have also been shown to inhibit fibrinolysis by PAI-1-
independent mechanisms7, and the individual role of other serpins, in the thrombolytic 
process has not yet been defined. Protease nexin-1 (PN-1), also known as SERPINE2, 
deserves special attention since it has been shown in vitro to inhibit significantly uPA, tPA 
and plasmin. PN-1 is barely detectable in plasma8 but is produced by various cell types9, and 
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interestingly, stored in the α-granules of platelets10
 The present paper evaluates, by in vitro and ex vivo studies, the role of platelet PN-1 
in platelet-rich clot (PRC) lysis. Moreover, we have developed a murine model of 
thrombolysis and applied it to wild-type and PN-1-deficient mice to test the hypothesis that 
PN-1 inhibits thrombolysis initiated by recombinant tPA. Thus, PN-1 may be a potential 
target to improve the therapeutic applications of thrombolytic agents. 
. Because of its action on proteases of the 
plasminergic system, we hypothesized that platelet PN-1 may play a prominent role in the 
process of thrombolysis resistance. 
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Materials and methods 
Animals 
PN-1-deficient mice (PN-1-/-) come from Pr D. Monard’s laboratory (FMI, Basel, 
Switzerland) and were back-crossed for 12 generations into the C57BL/6 line11
 
. Experimental 
animals were 8-16 weeks of age. Heterozygous mating generated PN-1-/- and wild-type mice 
(WT). Mice were bred and maintained in our own laboratory (Paris, France). All animals 
were genotyped by PCR. All experiments were performed in accordance with European 
legislation on the protection of animals. 
Methods 
Preparation of washed platelets 
 Human platelets 
Human blood from healthy adult volunteers was collected into 1/10 vol. ACD-A (38 mM 
citric acid, 60 mM sodium citrate, 136 mM glucose). Washed platelets were isolated as 
previously described12
 Mouse platelets 
. 
Blood was collected from anesthetized mice by cardiac puncture into syringes containing 1/10 
vol. ACD-C (130 mM citric acid, 124 mM sodium citrate, 110 mM glucose). Washed 
platelets were isolated as previously described10
 
. 
Binding of tPA and plasmin to fibrin matrices, and measurement of plasmin generation 
or activity. 
Fibrin matrices in 96-well plates were prepared as previously described13. The functionality of 
this fibrin surface was determined by measuring the activation of plasminogen by fibrin-
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bound t-PA, or the activity of fibrin-bound plasmin itself (See the online-only Method 
supplement). 
 
SDS-polyacrylamide gel electrophoresis and zymography. 
Platelets (5×108 /mL in reaction buffer) were activated by PAR1-AP (PAR1-activating 
peptide, SFLLRN, NeoMPS) (50 µM) for human platelets or by PAR4-AP (PAR4-activating 
peptide, AYPGKF, NeoMPS) (250 µM) for mouse platelets, for 30 minutes at 37°C. Control 
samples were obtained by incubating platelets for the same time with buffer. At the end of the 
incubation, samples were centrifuged and the supernatants (secreted fraction) were removed 
for analysis. The secreted fractions were incubated with recombinant tPA (10 IU/ml) or 
plasmin (0.25µM) for 30 minutes at 37°C in the presence or absence of the blocking anti-PN-
1 (generous gift from Dr D.Hantai, Inserm U582, Paris) or anti-PAI-1 IgGs (MA-33B8-307; 
Molecular Innovations). Proteins were first separated on a 10% SDS-polyacrylamide gel. 
After incubation with 2% Triton X-I00, the gel was then overlaid on a fibrin-plasminogen 
(200 nM)-agar gel, for tPA activity measurement, or on a fibrin-agar gel for plasmin activity, 
as previously described14. Zymograms were allowed to develop at 37°C during 24 hours and 
photographed at regular intervals using dark-ground illumination. Zymograms were stained 
with blue-coomassie15
 
.  
Clot formation and fibrinolysis ex vivo  
Human PRP was obtained from citrated blood by centrifugation at 120g during 15 minutes. 
PRP was adjusted at 108 platelets/ml in platelet free plasma and supplemented with 75µg/ml 
FITC-fibrinogen. For mouse PRCs, citrated human platelet-free plasma was mixed with 
murine washed platelets to a concentration of 8 × 108/ml. Samples were incubated with 
irrelevant-IgG or the blocking anti-PN-1 IgG or/and anti-PAI-1 IgG both at 100 µg/ml and 
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recalcified with 10 mM CaCl2 in glass tubes. After retraction, clots were removed, blotted and 
weighed. To assess fibrinolysis, clots were incubated in Hanks buffer (Sigma) for 24 hours at 
37°C. The supernatant was removed, and the fluorescence released from the clot was 
measured in a spectrofluorometer16
 
. The remaining clots were blotted and reweighed to 
calculate the loss of clot weight, and then were totally dissolved to calculate the fluorescence 
remained in the clot. 
Fibrinolysis experiments: microscopic lysis velocity by laser scanning confocal 
microscopy 
Citrated human or mice PRP was adjusted at 108 platelets/ml and supplemented with Alexa 
488-fibrinogen (Invitrogen). Human PRP was incubated with control IgG (Jackson 
immunoresearch) or blocking anti-PN-1 IgG (100 µg/ml) and PRCs were obtained by adding 
tissue factor (TF, Innovin 1/5 (v/v)) (Diagnostica Stago) and 10 mM CaCl2 in microchambers 
as previously described17
 
. PRP from WT or PN-1 -/- mice was clotted in the same conditions. 
Clots were scanned with a LEICA confocal laser scanning microscope linked to a Leica 
inverted microscope equipped with a ×63 water immersion objective. Scans were collected in 
a format of 512×512 pixels with 1024 gradations of intensity. Recombinant tissue 
plasminogen activator (rtPA, 26nM) (Alteplase, Boerhinger) was loaded at the edge of the 
labelled PRC. The edge of the clot was visualized with the confocal microscope set up in the 
reflection mode. Scanning was performed at a magnification 125 × 125 µm every 15 seconds 
for 30 minutes. The velocity of the lysis front was determined from confocal microscope 
images and analysed with image J software.  
ROTEM® Modified Rotation Thrombelastogram Analyzer 
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Citrated PRP was obtained and adjusted at 108 platelets/ml as described above. ROTEM® 
analysis was performed in pre-warmed ROTEM® cup containing 300 µl of PRP in presence of 
control IgG or the blocking anti-PN-1 or/and anti-PAI-1 IgG both at 100 µg/ml. Clotting was 
initiated by the addition of TF (Innovin 1/5 (v/v)), CaCl2 (10 mM). Fibrinolysis was initiated 
by the addition of human r-tPA (0.5 nM) (Alteplase, Boerhinger) or mouse r-tPA (30 nM) 
(Molecular Innovation). The fibrinolytic response by rtPA was assessed using ROTEM® 
software, thereby providing 
 
the lysis rate at 60 minutes in each condition. 
Dorsal skinfold chamber 
Dorsal skinfold chambers were implanted in 10- to 12-week-old mice (25 to 30 g body 
weight) anesthetized by intraperitoneal injection of 100 mg/kg ketamine and 10 mg/kg 
xylazine in saline solution as previously described18
 
. Briefly, a patch of dorsal hair was 
removed, and two titanium frames were positioned so as to sandwich the extended double 
layer of skin. One layer of betadine-cleaned skin was completely removed in a circular area of 
13 mm in diameter, and the remaining layer, consisting of epidermis, subcutaneous tissue, and 
striated skin muscle, was covered with a 12-mm glass coverslip incorporated in the frame. 
Following surgery, mice were injected subcutaneously with buprenorphine (0.05 mg/kg) and 
then again 8–12 h later. The animals tolerated the chambers well and showed no sign of 
discomfort. After a 48 h-period of recovery from surgery, preparations fulfilling the criteria of 
intact microcirculation and showing no signs of inflammation were utilized for thrombosis 
and thrombolysis experiments. 
Real-time intravital imaging of thrombus formation and thrombolysis. 
Mice were anesthetized with 100 mg/kg ketamine and 10 mg/kg xylazine and vascular injury 
was induced by placing a Whatman filter paper strip (1 x 0.5 mm) saturated with 15 % FeCl3 
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(Sigma) over venules (ranging from 130 to 160 µm diameter) in dorsal skinfold chambers for 
3 minutes. Thrombus formation following vessel injury was examined in real-time by 
monitoring the accumulation of rhodamine 6G (Sigma) (3 mg/kg mouse)–labelled platelets 
using an inverted fluorescence microscope (Axio Observer, Carl Zeiss MicroImaging GmbH, 
Germany) with a 5x objective connected to a Hamamatsu Orca-R2 charge-coupled device 
video camera
 
. Platelet deposition and thrombus growth in injured venules were monitored 
until vessel occlusion defined as a complete arrest of blood flow for at least 5 minutes. 
Immediately after vessel occlusion, 20 µl of saline containing rtPA (80 µM) and hirudin (10 
µM) (Serbio) were applied topically in the chamber to enhance thrombolysis, and prevent 
rethrombosis. Thrombolysis was analyzed by measuring the occurrence of recanalization of 
occluded venules, the time to recanalization, and the decrease in thrombus area at 30 minutes 
and 1 hour after rtPA treatment. A total of 13 venules in 7 PN1 –/– mice and 13 venules in 7 
WT mice were studied. Data acquisition and analysis were done using the Axiovision 
software (Carl Zeiss MicroImaging GmbH, Germany). 
Statistical analysis 
Results are shown as means ± SEM. Students t test was used for in vitro experiments with 
recombinant PN-1, in vitro experiments of wild-type and PN-1-deficient mice, and for lysis 
front velocity experiments. The one-way ANOVA followed by Dunnett’s test was used 
when comparisons of anti-PN-1 IgG or anti-PAI IgG groups versus Control IgG were 
performed. A linear mixed-effects model (LME) was used for the analysis of in vivo 
thrombolysis. A P value less than or equal to 0.05 was considered significant. 
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Results 
PN-1 inhibits plasminogen activation by fibrin-bound tPA  
 Plasminogen activation by tPA, was measured on a fibrin surface, in the presence or 
absence of recombinant PN-1. First, tPA was incubated for 1 hour on fibrin-coated plates, the 
excess of unbound tPA being eliminated. PN-1 was subsequently added to the fibrin-coated 
plates and the excess discarded. Plasmin generation induced by the residual fibrin-bound tPA 
was then determined after addition of plasminogen with the chromogenic substrate CBS0065. 
The initial rate of plasmin generation by tPA decreased by ~ 2fold in the presence of PN-1 
(Figure 1A): 2.7 ± 0.3 nM and 1.3 ± 0.1 nM plasmin were generated, respectively in the 
absence and presence of PN-1 (Figure 1B). 
 tPA-induced fibrin degradation was measured by fibrin-plasminogen-agar 
zymography with platelet releasates. Recombinant tPA induces a lysis area reflecting 
fibrinolytic activity relative to the amount of plasmin converted from plasminogen by tPA. As 
expected, the fibrin zymography lysis band corresponding to tPA was reduced by 
recombinant PN-1 (Figure 1C). No reduction in tPA induced-lysis area was observed after 
tPA incubation with the supernatant of resting human platelets. In contrast, when tPA was 
incubated with the secretion products of activated human platelets, the fibrin zymography 
lysis t-PA-band was barely detected, indicating the secretion of tPA inhibitor(s) by activated 
platelets (Figure 1C). To determine whether PN-1 contributed to fibrinolysis inhibition, 
zymography experiments were performed in the presence of a PN-1-blocking antibody. tPA 
activity was restored in the presence of the anti-PN-1 IgG (Figure 1C) but not in the presence 
of an irrelevant IgG (not shown). To confirm these findings, the same experiments were 
performed with platelets from PN-1-deficient mice and their littermate controls. Incubation of 
tPA with the secretion products of activated platelets from WT mice resulted in an almost 
complete inhibition of lysis (Figure 1D). On the contrary, the products secreted by platelets 
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from PN-1-/- did not decrease the tPA-induced lysis area (Figure 1D). Together, these data 
demonstrate that PN-1 has the remarkable capacity to inhibit the generation of plasmin 
induced by tPA bound to fibrin. 
 
PN-1 inhibits fibrin-bound plasmin  
 Degradation of fibrin by the serine protease, plasmin, is a step in the fibrinolysis 
process where PN-1 can also play an important role. To test this hypothesis, plasmin activity 
was measured on a fibrin surface, in the presence or absence of recombinant PN-1. The initial 
rate of substrate hydrolysis induced by fibrin-bound plasmin decreased by ~10-fold in the 
presence of PN-1 (Figure 2A-B). Fibrin-bound plasmin activity was thus drastically inhibited 
by PN-1. 
 Plasmin-induced fibrin degradation was measured by using fibrin-agar zymography. 
Similarly to the results obtained with tPA, we observed that the secretion products of 
activated platelets inhibited plasmin-induced lysis. This inhibition was completely prevented 
by the blocking anti-PN-1 antibody (Figure 2C). Fibrin-agar zymography was also performed 
with platelets from PN-1-deficient mice and their littermate controls. Incubation of plasmin 
with the secretion products of activated platelets from WT mice resulted in an almost 
complete inhibition of lysis (Figure 2D). On the contrary, the products secreted by platelets 
from PN-1-/- mice did not reduce plasmin-induced lysis area (Figure 2D). Our results thus 
demonstrate that PN-1 secreted by activated platelets is able to inhibit the fibrinolysis induced 
by fibrin-bound plasmin  
 
Platelet PN-1 limits PRC lysis 
 To test the functional effect of PN-1 on endogenous clot lysis, human platelet-rich 
plasma (PRP) containing FITC-fibrinogen, was preincubated with a control IgG or the 
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blocking anti-PN-1 IgG before clotting. Fibrinolysis was then assessed by clot weight loss and 
fluorescence release from the clot after 24 hours at 37°C. In the presence of a control IgG, 
clot weight loss was 7 ± 1 mg, whereas preincubation with the anti-PN-1 IgG resulted in a 
large increase in clot weight loss, reaching 27 ± 2 mg (Figure 3A). A blocking anti-PAI-1 IgG 
also enhanced clot weight loss by 17 ± 5 mg, although this increase was not statistically 
significant. The combination of both blocking antibodies resulted in a large increase in clot 
weight loss, reaching 46 ± 10 mg (Figure 3A). The percentage of FITC released from the clots 
was also significantly higher in the presence of the anti-PN-1 IgG (37 ± 2 %) than in the 
presence of an irrelevant IgG (26 ± 1 %) (Figure 3B). The same experiments were performed 
with PRP from WT and PN-1-deficient mice. Clot weight loss was greater for fibrinolysis 
with PN-1-/- clots (55 ± 6 mg) than with WT clots (31 ± 2 mg) (Figure 3C), and the 
percentage of released fluorescence was higher for PN-1 -/- (89 ± 3 %) than for WT clots (64 
± 3 %) (Figure 3D). Together, these results show that, in the absence of PN-1, endogenous 
tPA-induced clot lysis is enhanced within 24 hours, indicating that platelet PN-1 is a regulator 
of endogenous clot lysis. 
 The effect of PN-1 inhibition or PN-1-deficiency on clot lysis was further investigated 
using a ROTEM® analyser. An exogenous supplement of a subthreshold lytic concentration of 
tPA (0.5 nM) was used to induce clot lysis. As shown in Figures 4A and 4B, the percentage of 
tPA-induced clot lysis was minimal in the presence of a control IgG, reaching 16 ± 2%, while 
it was greatly increased in presence of the anti-PN-1 IgG, reaching 42 ± 5%. A blocking anti-
PAI-1 IgG also has an increased tendency for clot lysis by 28 ± 5 %, although it was 
statistically insignificant. The combination of both blocking antibodies resulted in an almost 
complete clot lysis at 60 minutes (91 ± 1 % of lysis). To substantiate these results, 
experiments were also performed using mouse platelets (Figure 4C). The ROTEM® tracing 
showed that a subthreshold concentration of tPA induced lysis of WT clots by 56 ± 7 % 
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whereas lysis of PN-1-deficient clots was almost complete (84 ± 8 %) under our experimental 
conditions (Figure 4D). These results indicate that both PN-1 and PAI-1 released by activated 
platelets contribute to inhibit tPA-induced clot lysis. 
 
Platelet PN-1 reduces the velocity of clot lysis 
 We visualized the lysis front of PRC by using laser scanning confocal microscopy 
(Figure 5). Addition of tPA at the edge of the microchambers of PRC initiated lysis with a 
straight and sharp front moving across the entire fibrin surface. A significant increase in the 
lysis front velocity was observed in the presence of the blocking anti-PN-1 IgG with an 
average rate of 22.5 ± 2.8 µm/minute compared to the control IgG 11.8 ± 1.6 µm/minute , (P< 
0.01 n=5 ) (Figure 5A). To confirm these findings, the same experiments were performed 
with clots from PN-1-deficient mice and their littermate controls. As observed with human 
clots, addition of tPA resulted in an acceleration of the lysis front in PN-1-deficient clots with 
a rate of 16.0 ± 1.5 µm/minute versus 10.3 ± 0.9 µm/minute with the WT clots (P< 0.05 n=5 ) 
(Figure 5B). 
 
tPA-induced thrombolysis is enhanced in PN 1-/- mice. 
 To determine whether the antifibrinolytic effect of PN-1 is of in vivo relevance, we 
have developed in mice, a method in which thrombolysis can be measured by intravital 
microscopy using the dorsal skinfold chamber model. We compared the efficiency of tPA-
induced thrombolysis in WT and PN-1 -/- mice (Figure 6A). Topical application of FeCl3 
over venules ranging from 130 to 160 µm in diameter was used to induce vascular injury 
leading to occlusive thrombosis. While there was no significant difference in the occlusive 
thrombus size/area between WT and PN-1 -/- mice (34163µm2 ± 5459 µm2 vs 31656 ± 
4709µm2, n = 13 vessels from 7 mice per group), the time to reach complete occlusion was 
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significantly reduced in PN-1 -/- mice compared to WT mice, in agreement with data obtained 
in the mesenteric vessel thrombosis model 10. During the 24 hours following complete arrest 
of blood flow, spontaneous recanalization was observed in only 2 of 13 vessels out of 7 PN 1-
/-mice and in none of the 13 occluded vessels from WT mice. This indicates that spontaneous 
thrombolysis following FeCl3
 After the thrombolysis experiments, mice were kept under observation for 24 hours 
and euthanized. Four hours after tPA treatment, all vessels occluded by FeCl
 injury is a slow process in both WT and PN1-/- mice. In order 
to accelerate thrombolysis, tPA was directly added to the chamber 5 minutes following 
complete vessel occlusion. Hirudin was simultaneously added to prevent rethrombosis. In WT 
mice, the mean time to recanalization following tPA treatment was superior to 1 hour while it 
was of 13 ± 2 minutes in PN-1 -/- mice (n= 7 mice) (Figure 6A). Furthermore, 1 hour after 
tPA treatment, the incidence of recanalization was 15 % (2 of 13 vessels) in WT mice and 
reached 92 % (12 of 13 vessels) in PN1 -/- mice (Figure 6B). Thirty minutes after tPA 
treatment, thrombus size remained unchanged in WT mice (101.6 ± 7.2 % of initial size) 
whereas it was significantly reduced in PN-1 -/- mice (56.1 ± 8.5 % of initial size). At 1 hour 
post-tPA treatment, the thrombus size was reduced in WT but this reduction was less 
important than in PN-1 -/- mice (76.7 ± 6.3 % vs 42.8 ± 9.5 % of initial size) (Figure 6C). 
Altogether, these results confirm that PN1 is a potent inhibitor of tPA-induced thrombolysis 
in vivo. 
3
 
 injury were 
recanalized in both WT and PN1 -/- mice. Interestingly, all PN-1-deficient mice (7 out of 7) 
remained healthy the day following thrombolytic treatment, whereas 71% (5 out of 7) of WT 
mice were apathetic and showed signs of respiratory distress.  
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Discussion 
 In humans, platelet PAI-1 released locally after platelet activation is assumed to be a 
major contributor to the stabilization of the thrombus by inhibiting endogenous fibrinolysis 5 
6. However, PAI-1-independent mechanisms have also been proposed to contribute to 
platelet-dependent inhibition of fibrinolysis 7. The existence of other non-PAI-1 proteinases 
inhibitors able to reduce plasminogen activation and/or plasmin activity has previously been 
suggested 19. Our study also suggests a less important role for PAI- and reveals that an 
additional serpin plays an important role in inhibiting plasminogen activators and plasmin. 
Indeed, we show here for the first time that PN-1, which can accumulate at the sites of 
vascular injury due to its presence in platelets 10, is an important player in the control of 
fibrinolysis. The fact that PN-1 can down-regulate both plasmin generation and plasmin 
activity on the fibrin matrix highlights the potential influence of PN-1 on fibrinolysis. Indeed, 
the fibrin matrix is largely recognized as an essential actor in the fibrinolysis process. It is 
well known that tPA-mediated plasminogen activation is dependent on fibrin, which restricts 
fibrinolysis to the site of thrombus 20. Importantly, when bound to fibrin, tPA is protected 
from inhibition by PAI-1 21, 22. The inhibition of tPA by PAI-1 is decreased by 80-90 percent 
in the presence of fibrin, because PAI-1 has no access to the catalytic domain of fibrin-bound 
tPA 23. Moreover, the rate of inactivation of plasmin by α2-antiplasmin slows down very 
significantly when plasmin is bound to fibrin 24. Thus, whereas serine proteases of the fibrin-
bound plasminergic system are “protected” from their principal inhibitors, platelet PN-1 
appears to be one inhibitor capable of blocking them in situ. The blocking PAI-1 antibody 
alone led to a non significant increase in clot lysis, in agreement with previous data 
demonstrating that PAI-1-deficiency induced only mild hyperfibrinolysis 19. This suggests 
that PAI-1 alone is not sufficient in regulating the lysis of platelet-rich clots. The higher 
fibrinolytic capacity observed in the presence of both PN-1 and PAI-1 blocking antibodies 
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supports a synergic involvement of both proteins in the regulation of clot lysis. Moreover, 
platelet PN-1 can influence the lysis of fibrin clots generated spontaneously from PRP, 
without any exogenous tPA, but also after addition of recombinant tPA, indicating that PN-1 
is inhibitory not only on endogenous but also on exogenous tPA-mediated lysis. These points 
are of clinical relevance: first, because endogenous fibrinolysis is known to play a pivotal role 
in the evolution of thrombotic cardiovascular diseases and second, because this may relate to 
the failure of optimal reperfusion in approximately one half of STEMI patients who are 
treated with fibrinolytic agents. A polymorphism in PN-1 could possibly explain the 
heterogeneity in the therapeutic efficacy of thrombolytic agents. Moreover, the fact that the 
lysis front moves faster when the PRC is devoid of PN-1, may imply that PRCs are refractory 
to tPA-induced lysis in a PN-1-dependent manner and that platelet PN-1 may have a critical 
impact at the level of fibers in the fibrin clot. Further experiments are needed to clarify this 
potential implication of platelet PN-1 on clot structure. 
 PN-1 appears to be a particularly important actor both in the development and in the 
dissolution of a thrombus. Indeed, PN-1 is involved in thrombus generation and extension by 
its capacity to inhibit thrombin-mediated fibrin formation and platelet activation 10, and we 
demonstrate here that PN-1 is also involved in thrombolysis by its capacity to inhibit the local 
generation and activity of plasmin. Because of these opposing effects, it was of great interest 
to analyze the effect of PN-1-deficiency in the process of thrombus dissolution, in vivo. For 
this purpose, we have developed an original murine model of in vivo thrombolysis associating 
ferric chloride injury and the dorsal skinfold chamber model. This approach is a reproducible 
method to quantify thrombus formation and lysis induced by a topical application of tPA. 
This device has the great advantage of allowing direct visualization, via intravital video-
microscopy, of thrombus formation but also, which is the originality of our model, of 
thrombus lysis in living animals. We observed that tPA-triggered PRCs are more readily lysed 
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in PN-1-deficient mice than in WT mice, with both the rate and the extent of recanalization 
being increased in PN-1-/- mice. Our data thus demonstrate the important role of PN-1 in 
mediating the resistance of PRC to lysis.  We also observed that WT mice poorly survived 
thrombolysis and exhibited a global organ failure syndrome, in contrast to PN-1-deficient 
mice which supported well the procedure without exhibiting any clinical manifestations.  
 The fact that platelet PN-1 is so important to protect the developing thrombus from 
premature lysis may explain the reason why the role of PAI-1 in thrombolysis resistance is a 
subject of controversy. Indeed, none of the previous investigations studying PAI-1 role in 
thrombolysis failure took into account the contribution of PN-1. We suggest here that 
endogenous PN-1 can play an important role in the failure of thrombolytic therapy to restore 
arterial blood flow. Clearly, our findings should be considered in the design of new 
therapeutic strategies, which should include the inhibition of PN-1 by antibodies or synthetic 
compounds to improve the therapeutic efficacy of thrombolytic agents. 
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Figure legends 
 
Figure 1: Inhibition of fibrin-bound tPA activity by PN-1 
(A-B) tPA (2.5 nM) was bound to fibrin surfaces, and plasmin formation was recorded in 
absence or presence of recombinant PN-1 (10 nM), with the chromogenic substrate CBS0065. 
The curves represent the average of the raw data corresponding to the change in absorbance as 
a function of time in the absence and the presence of rPN-1. To simplify the plots, error 
standards are represented only every 20 or 40 min. (B) Rates of substrate hydrolysis were 
calculated from the initial velocity and compared to a plasmin standard curve. Data are 
representative of 3 different experiments, each performed in triplicate. *P < 0.05 significantly 
different from tPA alone. (C-D) Plasminogen activation by tPA was measured by fibrin-
plasminogen-agar zymography after incubation of tPA with the supernatant from resting 
platelets or activated platelets by PAR1-AP or PAR4-AP as described in Methods. tPA was 
incubated (C) with human platelet secretion products in the presence or absence of an anti-
PN-1 IgG, or (D) with platelet secretion products from WT and PN-1-/- mice. Data are 
representative of 5 separate experiments from different donors or mice. 
 
Figure 2: Inhibition of fibrin-bound plasmin activity by PN-1 
(A-B) Plasmin (50 nM) was bound to fibrin surfaces and its activity was measured in absence 
or presence of recombinant PN-1 (10 nM), with the chromogenic substrate CBS0065. The 
curves represent the average of the raw data corresponding to the change in absorbance as a 
function of time in the absence and the presence of rPN-1. To simplify the plots, error 
standards are represented only every 20 or 40 min. (B) Rates of substrate hydrolysis were 
calculated from the initial velocity and compared to a plasmin standard curve. Data are 
representative of 3 different experiments, each performed in triplicate. *** P < 0.001 
significantly different from plasmin alone. (C-D) Plasmin activity was measured by fibrin- 
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agar zymography after incubation of plasmin with the supernatant from resting platelets or 
activated platelets by PAR1-AP or PAR4-AP as described in Methods. Plasmin was incubated 
(C) with human platelet secretion products in the presence or absence of an anti-PN-1 IgG, or 
(D) with platelet secretion products from WT and PN-1-/- mice. Data are representative of 5 
separate experiments from different donors or mice. 
 
Figure 3: Effect of platelet PN-1 in PRC lysis 
(A-B) PRCs from PRP of healthy donors, in the presence of an irrelevant IgG or an anti-PN1 
IgG, or an anti-PAI-1 IgG or (C-D) PRCs from WT or PN-1-/- mice PRP, were incubated 
with FITC-fibrinogen prior to clot formation. (A, C) The percentage reduction in clot weight 
and (B, D) the percentage of released fluorescence were analyzed over 24 hours. Data are 
presented as means ± SEM of 5 independent experiments from different donors and mice. 
***P < 0.001, significantly different from control IgG or WT clots. *P < 0.05, significantly 
different from control IgG. **P < 0.01, significantly different from WT clots. 
 
Figure 4: Effect of platelet PN-1 on ROTEM®
(A) Representative human PRP thromboelastogram (ROTEM
 ex vivo clot lysis. 
®) profiles. PRP was 
preincubated with a subthreshold concentration of tPA in presence of an irrelevant IgG, or an 
anti-PN-1 IgG, an anti-PAI-1 IgG or both. (B) In each condition, the rate of fibrinolysis was 
assessed by the reduction of the amplitude of the thrombolelastogram profile at 60 minutes. 
(C) Representative mice PRP thromboelastogram (ROTEM®) profiles. WT and PN-1-/- PRPs 
were preincubated with a subthreshold concentration of tPA and (D) the rate of fibrinolysis 
was quantified at 60 minutes. Data are presented as means ± SEM of 5 independent 
experiments from different donors and mice. ***P < 0.001, significantly different from 
control IgG. **P < 0.01 significantly different from WT clots. 
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Figure 5: Effect of platelet PN-1 on lysis-front velocity 
PRCs were labelled with Alexa 488-fibrinogen. (A) A series of confocal micrographs 
showing the dynamic lysis by rtPA, of human PRCs in presence of an irrelevant IgG or an 
anti-PN-1 IgG. (B) Confocal images of the dynamic lysis from WT or PN-1-/- PRCs. 
Progressive lysis-front motions are visualized and confocal micrographs are representative of 
5 independent experiments from different donors and mice. Bar, 20µm. 
 
Figure 6: Effect of PN-1 on thrombolysis. 
(A) Representative intravital images of vessel recanalization after tPA-treatment following an 
occlusion induced by FeCl3
 
. Bar, 200µm. (B) Quantification of the incidence of recanalized 
vessels within 1 hour post tPA-treatment. (C) Analysis of thrombus size after tPA-treatment 
in WT and PN-1 -/- mice. Data are means ± SEM for 13 vessels injured in 7 mice per group. 
*P< 0.05 significantly different from WT mice at equivalent time post-tPA treatment. 
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